A high-grade glioma diagnosis—whether glioblastoma, anaplastic astrocytoma, or another WHO grade III or IV tumor—moves fast. Surgery may happen within days of your first scan. Decisions about radiation and chemotherapy follow quickly. The first month feels like a blur of appointments, new medical terms, and difficult decisions.
This checklist covers five essential actions to complete in your first 30 days: getting your pathology report, confirming which molecular tests were done, assembling your care team, getting a second opinion, and mapping out your treatment timeline before radiation starts.
Step 1: Get Your Pathology Report in Hand
Your pathology report is the foundation for every decision that follows. After surgery or biopsy, a neuropathologist examines your tumor tissue under a microscope. The report tells your care team what grade the tumor is, what cell type it came from, and whether specific molecular changes are present that affect how the tumor should be treated.
You have the legal right to a copy. Ask your care coordinator or neurosurgeon's office for it in writing. If you don't receive it automatically after discharge, request it that week.
Reading a pathology report is hard without medical training. Start by looking for a few key terms: grade, IDH status, MGMT promoter methylation, and for some tumor types, 1p/19q codeletion. These terms will come up in nearly every conversation your care team has about your treatment plan. Knowing what they mean helps you join the conversation instead of just listening.
Step 2: Confirm That the Right Molecular Tests Were Ordered
Modern neuropathology goes far beyond what a microscope alone can show. Since the World Health Organization updated its brain tumor classification in 2021, molecular markers are required to fully classify most high-grade gliomas. According to the National Institutes of Health, molecular testing is necessary to accurately classify and direct treatment for gliomas in routine clinical practice.
The markers that matter most for newly diagnosed high-grade glioma include:
- IDH mutation (IDH1 or IDH2): IDH-mutant tumors often do better than IDH wild-type tumors. This single result can change your diagnosis type, your prognosis category, and your eligibility for clinical trials.
- MGMT promoter methylation: This marker tells your team how likely your tumor is to respond to temozolomide chemotherapy. MGMT-methylated tumors tend to respond better.
- 1p/19q codeletion: Essential for oligodendrogliomas. Its presence confirms a distinct tumor type with different treatment sensitivities.
- TERT promoter mutation, EGFR amplification, and PTEN loss: These are increasingly tested in IDH wild-type glioblastoma and may affect clinical trial eligibility and treatment options.
If your pathology report doesn't include a full molecular panel, ask your neuro-oncologist whether additional testing is needed. Some community hospitals don't run every marker in-house. A reference laboratory can do the testing, but it takes extra days. Ask early. For details on which tests your tumor likely needs, see our article on what molecular tests a newly diagnosed glioblastoma needs and why they shape your treatment plan.
Step 3: Build Your Multidisciplinary Care Team
No single physician manages a high-grade glioma alone. Clinical guidelines for glioblastoma emphasize a multidisciplinary approach involving neuro-oncology, neurosurgery, radiation oncology, and neuropathology working together to get the best results.
At a minimum, your team should include:
- Neurosurgeon: Performed or will perform your resection or biopsy. Evaluates whether more surgery is appropriate now or later.
- Neuro-oncologist: Your primary brain tumor specialist. Coordinates chemotherapy, monitors your imaging, and oversees your overall treatment strategy.
- Radiation oncologist: Plans and delivers radiation therapy, which for most high-grade gliomas starts three to five weeks after surgery.
- Neuropathologist: Reviews your tissue and produces your pathology report. You may never meet this person, but their findings drive every decision your team makes.
Other specialists often involved in high-grade glioma care include:
- Neuroradiologist: Reads your MRI scans and helps distinguish tumor growth from pseudoprogression or radiation necrosis.
- Neuropsychologist: Assesses and helps manage the cognitive effects of the tumor and its treatment.
- Palliative care specialist: Focuses on symptom management and quality of life throughout treatment, not only at the end of it.
- Social worker or patient navigator: Helps with logistics, insurance, and connecting you to support resources.
The best care happens when these specialists talk regularly at a formal tumor board or multidisciplinary conference. A brain tumor board brings together neurosurgeons, neuro-oncologists, radiation oncologists, neuroradiologists, and other experts to review each patient's case and recommend the best next steps. When evaluating a treatment center, ask whether your case will be reviewed at a formal brain tumor board. That answer tells you a lot about the coordination you can expect.
Step 4: Seek a Second Opinion Before Radiation Starts
A second opinion isn't a sign of distrust. It's standard in cancer care and can reshape your plan. A second opinion may introduce treatment options or clinical trials that weren't initially offered at your diagnosing center.
A second opinion for a high-grade glioma typically includes:
- Independent review of your pre- and post-operative MRI scans
- Independent review of your pathology report and molecular markers
- Assessment of your surgical report and extent of resection
- An independent recommendation on your treatment plan and timing
Major cancer centers like Memorial Sloan Kettering, Dana-Farber, and Mayo Clinic offer remote second-opinion services. You don't have to live nearby.
Timing matters. Radiation usually starts three to six weeks after surgery. That's a tight window, but usually enough time to send your records to another center and get a response. Begin the process within the first few days of your initial consultation, not weeks later.
If your pathology report is unclear—maybe the molecular panel isn't complete or the tumor classification seems uncertain—ask about reviewing the pathology slides again. Our article on when a second opinion on your glioma pathology and molecular testing matters walks through this step in detail.
Step 5: Map Your Treatment Timeline
Treatment for high-grade gliomas includes surgery, radiation, and chemotherapy. For glioblastoma and other grade III-IV tumors, radiation and chemotherapy usually happen at the same time over several weeks. Clinical guidance from the National Institutes of Health indicates that for newly diagnosed high-grade gliomas, radiation therapy typically begins three to five weeks after surgery.
A general framework for the first several months often looks like this:
- Weeks 1 to 3 (post-surgery): Recovery and wound healing. Steroid taper. Awaiting final pathology results. Pursuing a second opinion if desired. Radiation simulation scan (planning MRI or CT).
- Weeks 3 to 7: Chemoradiation begins. Radiation is delivered over multiple weeks, often with concurrent oral chemotherapy.
- Weeks 8 to 10: A short break after chemoradiation ends. Follow-up MRI to assess initial response and rule out pseudoprogression.
- Months 3 onward: Adjuvant chemotherapy cycles. Regular imaging at intervals set by your neuro-oncologist.
Some glioblastoma patients also use Tumor Treating Fields (TTFields), a device that delivers electric fields through a wearable scalp cap. It usually starts after chemoradiation ends. Our article on how TTFields work, who qualifies, and what to expect during treatment covers this option in full.
Your specific timeline depends on your tumor's location, how well you're functioning, your age, and your molecular markers. Ask your neuro-oncologist to walk you through your treatment plan before it starts—which drugs will be used and when. Knowing what's coming helps you manage stress and prepare for each phase.
Step 6: Handle the Practical Side Early
The first month after diagnosis is medically intense and logistically demanding. Getting organized early reduces stress and prevents unnecessary delays.
Medical records and imaging: Get copies of your MRI images (on disc or digital), your pathology report, your operation notes, and your discharge summary. You'll need these for any second opinion and for clinical trial screening.
Insurance authorization: Your insurance usually needs to approve radiation and chemotherapy before they start. Ask your care team's billing or patient services department to begin this as soon as your treatment plan is confirmed. Delays in authorization can delay your radiation start date.
Clinical trial screening: Trials for newly diagnosed high-grade glioma often require enrollment before or early during chemoradiation. If you want to join a trial, search ClinicalTrials.gov early. Ask your doctor if any studies match your tumor type and how you're doing.
Your support person: Pick someone you trust—a family member, friend, or patient advocate—to help with appointments, note-taking, and paperwork. Steroids and stress affect your thinking. A second set of ears in the room helps from day one.
When to Talk to Your Doctor
Contact your care team promptly if you develop new or worsening neurological symptoms after surgery—sudden weakness, difficulty speaking, new seizures, or vision changes. These need urgent care and might delay radiation.
Also raise these concerns at your next appointment if you haven't already:
- Your pathology report doesn't include IDH testing or MGMT methylation status
- You haven't been referred to a neuro-oncologist within one to two weeks of hospital discharge
- You're unsure whether your treating center has a formal brain tumor multidisciplinary team
- You want to pursue a second opinion and need help transferring records
- You have questions about clinical trial eligibility or other options you want to explore alongside your standard treatment
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.